Koers Jaguar Health Inc Nasdaq
Aandelen
US47010C2017
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 15,11 mln. 14,13 mln. | Omzet 2025 * | 22,66 mln. 21,19 mln. | Marktkapitalisatie | 19,6 mln. 18,33 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,31 mln. | Nettowinst (verlies) 2025 * | -21 mln. -19,64 mln. | EV/omzet 2024 * | 1,3 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,86 x |
K/w-verhouding 2024 * |
-0,69
x | K/w-verhouding 2025 * |
-0,88
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 87,25% |
Recentste transcriptie over Jaguar Health Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 06-06-13 |
Carol Lizak
DFI | Director of Finance/CFO | 60 | 01-05-19 |
Chief Tech/Sci/R&D Officer | 60 | 01-05-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 06-06-13 |
James Bochnowski
CHM | Chairman | 80 | 01-02-14 |
John Micek
BRD | Director/Board Member | 71 | 01-04-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,73% | 124 mld. | |
+16,88% | 111 mld. | |
-9,04% | 23,17 mld. | |
+5,39% | 22,94 mld. | |
-38,15% | 17,42 mld. | |
-7,75% | 17,42 mld. | |
-15,24% | 16,9 mld. | |
+3,42% | 13,71 mld. | |
+29,63% | 11,82 mld. |